Amarnath Challapalli, Amer Durrani, Grant Stewart, Heather Shaw, John Lear, Kate Fife, Kim Peate, Miranda Payne, Ricky Frazer, Jonathan Pollock
{"title":"A UK Delphi consensus study on the definition and management of advanced cutaneous squamous cell carcinoma.","authors":"Amarnath Challapalli, Amer Durrani, Grant Stewart, Heather Shaw, John Lear, Kate Fife, Kim Peate, Miranda Payne, Ricky Frazer, Jonathan Pollock","doi":"10.1080/14796694.2026.2733721","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Advanced cutaneous squamous cell carcinoma (acSCC) encompasses locally advanced and metastatic disease; however, no standardized definition exists. Recognition and categorization, therefore, often rely on multidisciplinary judgment, which may lead to variations in diagnosis and management between centers. This study aimed to establish United Kingdom (UK) consensus on the definition and optimal management of acSCC.</p><p><strong>Methods: </strong>A modified Delphi methodology was followed. Ten senior clinicians formed a steering group and identified four key topics for consensus statement development surrounding the challenges of acSCC, disease definition, assessment, and optimal management. Forty-two consensus statements were developed and distributed via an online survey to UK clinicians experienced in acSCC care. Agreement was rated on a 4-point Likert scale, with consensus predefined as ≥75% agreement.</p><p><strong>Results: </strong>A total of 130 responses were received from dermatologists, oncologists, surgeons, and clinical nurse specialists, among others. The consensus threshold was met for 39 of 42 statements (93%). A consensus definition, eight best-practice recommendations, and a treatment algorithm were developed.</p><p><strong>Conclusion: </strong>This study provides a UK-derived definition of acSCC, addressing the current lack of agreed terminology. The study outputs may help standardize disease classification, reduce practice variation, and support more consistent management of acSCC across UK services.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"2693-2708"},"PeriodicalIF":3.1000,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2026.2733721","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/9/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Advanced cutaneous squamous cell carcinoma (acSCC) encompasses locally advanced and metastatic disease; however, no standardized definition exists. Recognition and categorization, therefore, often rely on multidisciplinary judgment, which may lead to variations in diagnosis and management between centers. This study aimed to establish United Kingdom (UK) consensus on the definition and optimal management of acSCC.
Methods: A modified Delphi methodology was followed. Ten senior clinicians formed a steering group and identified four key topics for consensus statement development surrounding the challenges of acSCC, disease definition, assessment, and optimal management. Forty-two consensus statements were developed and distributed via an online survey to UK clinicians experienced in acSCC care. Agreement was rated on a 4-point Likert scale, with consensus predefined as ≥75% agreement.
Results: A total of 130 responses were received from dermatologists, oncologists, surgeons, and clinical nurse specialists, among others. The consensus threshold was met for 39 of 42 statements (93%). A consensus definition, eight best-practice recommendations, and a treatment algorithm were developed.
Conclusion: This study provides a UK-derived definition of acSCC, addressing the current lack of agreed terminology. The study outputs may help standardize disease classification, reduce practice variation, and support more consistent management of acSCC across UK services.
期刊介绍：
Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.
The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
